Tag: Bdq

As of 2024, approximately half a million people globally are estimated to become ill with multidrug-resistant or rifampicin-resistant tuberculosis annually. This public health crisis has made the development of novel treatments critical, leading to the introduction of BDQ, or bedaquiline, a medication used to combat these stubborn infections.

According to the World Health Organization (WHO), over 10 million people fall ill with tuberculosis (TB) each year. BDQ, or bedaquiline, is a groundbreaking medication used as a cornerstone in the treatment of drug-resistant forms of this infectious disease, including multi-drug resistant (MDR-TB).